Valneva SE (VALN) Cost of Revenue (2021 - 2026)
Valneva SE's (VALN) quarterly Cost of Revenue came in at $30.7 million in Q1 2026, up 26.45% year-on-year from $24.2 million in Q1 2025, and down 27.0% quarter-over-quarter from $42.0 million in Q4 2025.
Valneva SE (VALN) Cost of Revenue (2021 - 2026) Analysis & Trends
Valneva SE has disclosed Cost of Revenue across 6 years of filings, most recently posting $30.7 million for Q1 2026.
- Cost of Revenue for Q1 2026 came in at $30.7 million, up 26.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $127.9 million (up 19.73% YoY), and the FY2025 annual result was $124.7 million, up 18.44% from the prior year.
- Cost of Revenue came in at $30.7 million for Q1 2026 at Valneva SE, down from $42.0 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $168.2 million in Q2 2022 to a low of $15.6 million in Q1 2022.
- The 5-year median for Cost of Revenue is $28.0 million (2023), against an average of $41.6 million.
- Peak annual rise in Cost of Revenue reached 593.86% in 2022, while the deepest fall reached 78.59% in 2022.
- Valneva SE's Cost of Revenue stood at $124.2 million in 2022, then slumped by 77.42% to $28.0 million in 2023, then advanced by 3.76% to $29.1 million in 2024, then jumped by 44.29% to $42.0 million in 2025, then slipped by 27.0% to $30.7 million in 2026.
- The last three Cost of Revenue figures came in at $30.7 million (Q1 2026), $42.0 million (Q4 2025), and $27.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 64.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 48,670.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 392.80 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 2.05 Mn |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | 30.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.65 Mn |
| Mar 31, 2026 | 30.65 Mn |
| Dec 31, 2025 | 41.99 Mn |
| Dec 31, 2025 | 41.99 Mn |
| Sep 30, 2025 | 27.95 Mn |
| Sep 30, 2025 | 27.95 Mn |
| Jun 30, 2025 | 27.30 Mn |
| Jun 30, 2025 | 27.30 Mn |
| Mar 31, 2025 | 24.24 Mn |
| Mar 31, 2025 | 24.24 Mn |
| Dec 31, 2024 | 29.10 Mn |
| Dec 31, 2024 | 29.10 Mn |
| Sep 30, 2024 | 28.20 Mn |
| Sep 30, 2024 | 28.20 Mn |
| Jun 30, 2024 | 25.27 Mn |
| Jun 30, 2024 | 25.27 Mn |
| Mar 31, 2024 | 24.07 Mn |
| Mar 31, 2024 | 24.07 Mn |
| Dec 31, 2023 | 28.04 Mn |
| Dec 31, 2023 | 28.04 Mn |